7.35 0.00 (0.00%)
After hours: 4:47PM EDT
|Bid||0.00 x 900|
|Ask||7.75 x 800|
|Day's Range||7.30 - 7.80|
|52 Week Range||2.37 - 9.93|
|Beta (3Y Monthly)||4.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT The Last Review? CEL-SCI Corporation (NYSE:CVM) today announced its second Independent Data Monitoring Committee (IDMC) review this year for the IT MATTERS Phase III Multikine study for head and neck cancer. We believe that the longer than expected duration of the trial combined with the IDMC recommendation to continue its
CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The IDMC meets periodically to review the safety and efficacy of the ongoing Phase 3 study.
By John Vandermosten, CFA NYSE:CVM While CEL-SCI (NYSE:CVM) has experienced outstanding performance over the last several quarters due to the anticipated readout of Multikine in the IT-MATTERS clinical trial, the company also has a platform technology in development that has impressive potential in treating a number of human diseases. This platform is known as the Ligand
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the H.C. Wainwright 21st Annual Global Investor Conference on Tuesday, September 10th at 11:15 a.m. Eastern Time. A live webcast of Mr. Kersten’s presentation will be available in the Investors section of the Company's website at https://cel-sci.com/new-investor-information/. CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival.
In late May 2019, Zacks was treated to an onsite tour of CEL-SCI’s (CVM) 73,000 square foot manufacturing facility in Elkridge, Maryland. As we drove to the industrial park southwest of Baltimore, we came upon CEL-SCI’s facility, nestled among warehouses and light manufacturing enterprises. With multiple delivery bays and administrative offices up front, we entered to meet with Chief Scientific Officer Dr. Eyal Talor who introduced us to the staff and provided background on the facility in preparation for our walk through.
OncoCyte Corporation (NYSE: OCX ) is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes July 1. The Russell 3000 Index is a capitalization-weighted stock market index maintained by ...
CEL-SCI Corporation (NYSE American: CVM) is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 10:40 a.m. PT. Geert Kersten, Chief Executive Officer of CEL-SCI, will be giving the presentation. Mr. Kersten’s presentation will be webcast and available in the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/.
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reported fiscal second quarter 2019 results for the three month period ending March 31, 2019. A the end ...
The Vienna, Virginia-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring costs, were 19 cents per share. The cancer immunotherapy company posted revenue of $150,800 ...
CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2019. The Company also reported key clinical and corporate developments achieved during the quarter.
This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine. CEL-SCI Corporation (NYSE American: CVM) announced today that Daniel Zimmerman, Ph.D., its Senior Vice President of Research, Cellular Immunology, presented new LEAPS data at the American Association of Immunologists 103th Annual Meeting (Immunology 2019) in San Diego, California on Saturday, May 11, 2019.
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the ThinkEquity Conference in New York, NY on Thursday, May 2, 2019 at 1:00 p.m. A live audio webcast of the presentation and replay will be available on CEL-SCI's website at https://cel-sci.com/new-investor-information/. CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival.
NEW YORK, March 26, 2019 -- Levi & Korsinsky announces it has commenced an investigation of CEL-SCI Corporation (NYSEAMERICAN: CVM) concerning possible breaches of.
CEL-SCI Corporation (NYSE American: CVM) today announced it has been selected by the U.S. National Institutes of Health (NIH) for sponsorship to exhibit and showcase its presentation for its LEAPS technology at the BIO International Convention, to be held June 3-6, 2019 in Philadelphia. LEAPS, which is currently being developed as a therapeutic vaccine for rheumatoid arthritis under a $1.5 million SBIR/STTR grant from the NIH, will be featured at the convention’s Innovation Zone, a turn-key exhibit space dedicated to showcasing select NIH SBIR/STTR awardees.
CEL-SCI Corporation (NYSE American:CVM) today announced the Journal of Clinical & Cellular Immunology has published an article titled, “Why Don’t We Have a Vaccine Against Autoimmune Diseases?” co-written by Dr. Ken Rosenthal of Roseman University College of Medicine, and CEL-SCI’s Roy Carambula, Research Associate and Daniel Zimmerman Ph.D., Senior Vice President of Cellular Immunology.
This assessment is based on historical event rates which suggests the final event will take place in the next few months. In CEL-SCI Corporation’s (CVM) a recent update to clinicaltrials.gov, we noticed that the anticipated completion was changed from December 2017 to December 2020. Management stated that the new anticipated completion date should read September 2019.
On a per-share basis, the Vienna, Virginia-based company said it had profit of 2 cents. Losses, adjusted for non-recurring gains, were 17 cents per share. The cancer immunotherapy company posted revenue ...